SLC5A2 and diabetes mellitus: Recent breakthrough studies on the pharmacological effects of sodium glucose cotransporter 2 (SGLT2) inhibitors, originally developed as diabetes medications, have highlighted their efficacy in treating not only diabetes mellitus but also heart failure and chronic kidney disease (CKD) (Scheen, 2020).